Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

RTOG 1071 / N0577 (Codel): Study of Radio-therapy with Concomitant and Adjuvant Temozolomide

Research Question:
Will giving temozolomide alone, radiation followed by PCV, or temozolomide together with radiation therapy followed by temozolomide be more effective in treating anaplastic glioma?

Basic Study Information

Purpose:
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.

Location: Cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT00887146?term=Temozolomide+Alone+versus+Radiotherapy+with+Concomitant+and+Adjuvant+Temozolomide+versus+Radiotherapy+with+Adjuvant+PCV&rank=1
Study Reference #: RBRN-11108

Lead Researcher (Principal Investigator)

Lead Researcher:  Yuhchyau Chen

Study Contact Information

Additional Study Details

Return to Search